Healthpeak Properties heads into its May 5 Q1 earnings with options traders notably more defensive than they have been all year.
The most striking signal is in the options market. The put/call ratio has climbed to 0.76, nearly 1.6 standard deviations above its 20-day average of 0.42 — the most defensive reading in recent months and well above where it spent most of April. That shift happened abruptly: the PCR sat below 0.25 for the first three weeks of April before jumping sharply after the 21st, right as the earnings date came into view.
The short-selling picture tells a calmer story. Short interest has eased, now at 4.4% of the free float, down roughly 3% on the week and pulling back from a brief April 17 spike that briefly pushed positions to a 52-week extreme. Days to cover run at around 5.9. Availability remains loose, and cost to borrow is just 0.49% — barely above the risk-free rate — signalling no meaningful pressure building in the lending market. The ORTEX short score has also declined from a recent high of 46.8 to 41.5, placing Healthpeak in the 28th percentile for short intensity within its sector. The borrow market is relaxed.
The more contested question heading into the print is the trajectory of the company's lab and medical office assets. Bulls point to a portfolio of roughly 700 properties, largely concentrated in medical office and life sciences, alongside $148 million in new development projects that are approximately 80% pre-leased and targeting mid-7% stabilised yields. That pipeline, if delivered, supports a gradual re-rating. Bears counter with deteriorating lab tenant credit quality, sluggish second-quarter leasing, and a revised FFO growth forecast that barely keeps pace with inflation — the CAGR for FFOPS over 2026–2027 is now projected in the range of +1% to -1%. Analysts have leaned cautious: Morgan Stanley's Richard Hill cut his price target to $18 this week while retaining an Overweight rating, and UBS initiated at Neutral with a $17 target on April 20. The consensus mean has drifted to $19.47, implying roughly 19% upside from the current $16.42 close — but the direction of recent moves is unmistakably downward. The RSI of 40 places the stock in mild oversold territory.
The May 5 report is therefore less about headline FFO than about lab occupancy trends and whether the leasing pipeline can hold up — the two variables that have driven the most significant target-price cuts across the Street in recent months.
See the live data behind this article on ORTEX.
Open DOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
